Show simple item record

dc.creatorLien, Chia-En
dc.creatorLin, Yi-Jiun
dc.creatorChen, Charles
dc.creatorLian, Wei-Cheng
dc.creatorKuo, Tsun-Yung
dc.creatorCampbell, John D.
dc.creatorTraquina, Paula
dc.creatorLin, Meei-Yun
dc.creatorLiu, Luke Tzu-Chi
dc.creatorChuang, Ya-Shan
dc.creatorKo, Hui-Ying
dc.creatorLiao, Chun-Che
dc.creatorChen, Yen-Hui
dc.creatorJan, Jia-Tsrong
dc.creatorMa, Hsiu-Hua
dc.creatorSun, Cheng-Pu
dc.creatorLin, Yin-Shiou
dc.creatorWu, Ping-Yi
dc.creatorWang, Yu-Chiuan
dc.creatorTao, Mi-Hua
dc.creatorLin, Yi-Ling
dc.date.accessioned2021-10-26T21:17:40Z
dc.date.available2021-10-26T21:17:40Z
dc.date.issued2021-04-22
dc.identifier.citationLien, CE., Lin, YJ., Chen, C. et al. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge. Sci Rep 11, 8761 (2021). https://doi.org/10.1038/s41598-021-88283-8
dc.identifier.issn2045-2322
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/7004
dc.identifier.urihttp://hdl.handle.net/20.500.12613/7023
dc.description.abstractThe COVID-19 pandemic presents an unprecedented challenge to global public health. Rapid development and deployment of safe and effective vaccines are imperative to control the pandemic. In the current study, we applied our adjuvanted stable prefusion SARS-CoV-2 spike (S-2P)-based vaccine, MVC-COV1901, to hamster models to demonstrate immunogenicity and protection from virus challenge. Golden Syrian hamsters immunized intramuscularly with two injections of 1 µg or 5 µg of S-2P adjuvanted with CpG 1018 and aluminum hydroxide (alum) were challenged intranasally with SARS-CoV-2. Prior to virus challenge, the vaccine induced high levels of neutralizing antibodies with 10,000-fold higher IgG level and an average of 50-fold higher pseudovirus neutralizing titers in either dose groups than vehicle or adjuvant control groups. Six days after infection, vaccinated hamsters did not display any weight loss associated with infection and had significantly reduced lung pathology and most importantly, lung viral load levels were reduced to lower than detection limit compared to unvaccinated animals. Vaccination with either 1 μg or 5 μg of adjuvanted S-2P produced comparable immunogenicity and protection from infection. This study builds upon our previous results to support the clinical development of MVC-COV1901 as a safe, highly immunogenic, and protective COVID-19 vaccine.
dc.format.extent7 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofCOVID-19 Research
dc.relation.haspartScientific Reports, Vol. 11
dc.relation.isreferencedbyNature Research
dc.rightsAttribution CC BY
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectDiseases
dc.subjectImmunology
dc.subjectMicrobiology
dc.titleCpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge
dc.typeText
dc.type.genreJournal article
dc.description.departmentBiology
dc.relation.doihttps://doi.org/10.1038/s41598-021-88283-8
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeTemple University. College of Science and Technology
dc.temple.creatorChen, Charles
refterms.dateFOA2021-10-26T21:17:40Z


Files in this item

Thumbnail
Name:
Chen-JournalArticle-2021-04.pdf
Size:
1.287Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY